The UK Adult Twin Registry (TwinsUK Resource)

Alireza Moayyeri, Christopher J. Hammond, Deborah J. Hart, and Timothy D. Spector
Department of Twin Research and Genetic Epidemiology, King’s College London, St. Thomas’ Hospital, London, UK

TwinsUK is a nation-wide registry of volunteer twins in the United Kingdom, with about 12,000 registered twins (83% female, equal number of monozygotic and dizygotic twins, predominantly middle-aged and older). Over the last 20 years, questionnaire and blood/urine/tissue samples have been collected on over 7,000 subjects, as well as three comprehensive phenotyping assessments in the clinical facilities of the Department of Twin Research and Genetic Epidemiology, King’s College London. The primary focus of study has been the genetic basis of healthy aging process and complex diseases, including cardiovascular, metabolic, musculoskeletal, and ophthalmologic disorders. Alongside the detailed clinical, biochemical, behavioral, and socio-economic characterization of the study population, the major strength of TwinsUK is availability of several ‘omics’ technologies for the participants. These include genome-wide scans of single nucleotide variants, next-generation sequencing, exome sequencing, epigenetic markers (MeDIP sequencing), gene expression arrays and RNA sequencing, telomere length measures, metabolomic profiles, and gut flora microbiomics. The scientific community now can freely access parts of the phenotype data from the ‘TwinsUK’, and interested researchers are encouraged to contact us via our Web site (www.twinsuk.ac.uk) for future collaborations.

Keywords: twin studies, genetic epidemiology, longitudinal studies, genome-wide association studies, next-generation sequencing, genomics, epigenomics, gene expression analysis, metabolomics, microbiomics

Introduction
The UK Adult Twin Registry (TwinsUK) is a cohort of volunteer adult twins from all over the United Kingdom. The Department of Twin Research and Genetic Epidemiology at St. Thomas’ Hospital, King’s College London (KCL) hosts the registry, which started in 1992 via media campaigns targeted at middle-aged women. The success of early studies led to rapid evolution of the registry and it now incorporates twins, both male and female, from other sources such as the Aberdeen Twin Registry and Institute of Psychiatry Adult Registry. The primary focus of study has been the genetic basis of complex diseases (cardiovascular, metabolic, musculoskeletal, and ophthalmologic diseases), which has broadened to include the complex healthy ageing process. The third health check of the volunteer twins has provided longitudinal data that, alongside with the state-of-the-art ‘omics’ technologies data, can significantly advance the field of genetic and clinical epidemiology of ageing. We have previously described the design of the original twin registry, facilities and procedures for data collection, clinical and biological assessments, and main findings in 2006 (Spector & Williams, 2006). The current article presents a brief update on the study procedures and recent technological applications in our cohort. More detailed description of phenotypes, research projects and collaborations, papers, and study findings can be accessed through our updated study Web site (http://www.twinsuk.ac.uk).

The Collection
The TwinsUK registry now consists of about 12,000 monozygotic (MZ) and dizygotic (DZ) twins aged 18 to 103 years (Table 1). About 83% of the registry is female (mean age of 55 years). The registry now contains 51% MZ and 49% DZ twins. Between 1992 and 2004, twins were invited for a full comprehensive visit and several project-led studies. More than 7,000 twins responded to some of the annual questionnaires and 5,725 attended a comprehensive visit. Apart from a lifelong lower weight in MZ twins of...
around 1 kg, all other age-matched characteristics of these 
volunteer twins were found not to differ from a single-
ton population-based cohort of British women (Chingford 
study; Andrew et al., 2001). Between April 2004 and May 
2007, all the 6,740 active twins on the registry were invited 
for a 1-day clinical visit, of whom 3,725 twins attended 
and confirmed via subsequent genotyping or genome-wide 
association studies. Zygosity status was assessed for all twins 
can be considered as representative of the original popula-
tion in the study.

The UK Adult Twin Registry

The second follow-up visit, also known as the HATS 
(Healthy Ageing Twin Study) visit, started in August 2007. 
Only women aged ≥40 years with at least one previous clinical 
visit (n = 4,610) were invited for this visit. In total, 3,725 
twins posted their blood DNA samples via their general 
practitioners. The age of participants ranged between 18 
and 82 years (mean 52.5 ± 13 years) and 3,299 of the 
clinic attendants (89%) were female.

The second follow-up visit, also known as the HATS 
(Healthy Ageing Twin Study) visit, started in August 2007. 
Only women aged ≥40 years with at least one previous clinical 
visit (n = 4,610) were invited for this visit. In total, 3,725 
twins posted their blood DNA samples via their general 
practitioners. The age of participants ranged between 18 
and 82 years (mean 52.5 ± 13 years) and 3,299 of the 
clinic attendants (89%) were female.

The second follow-up visit, also known as the HATS 
(Healthy Ageing Twin Study) visit, started in August 2007. 
Only women aged ≥40 years with at least one previous clinical 
visit (n = 4,610) were invited for this visit. In total, 3,725 
twins posted their blood DNA samples via their general 
practitioners. The age of participants ranged between 18 
and 82 years (mean 52.5 ± 13 years) and 3,299 of the 
clinic attendants (89%) were female.

The second follow-up visit, also known as the HATS 
(Healthy Ageing Twin Study) visit, started in August 2007. 
Only women aged ≥40 years with at least one previous clinical 
visit (n = 4,610) were invited for this visit. In total, 3,725 
twins posted their blood DNA samples via their general 
practitioners. The age of participants ranged between 18 
and 82 years (mean 52.5 ± 13 years) and 3,299 of the 
clinic attendants (89%) were female.
for clinical and genetic epidemiological studies (Moayyeri et al., 2012a). During the study follow-up, care has been
taken to perform key clinical tests with similar protocols
across all visits. Incident clinical endpoints (e.g., cardiovas-
cular events, stroke, fractures, osteoarthritis, and different
cancers) have been assessed over the course of study us-
ing questionnaires. Twins are all now registered using their
National Health Services (NHS) numbers with the Office
for National Statistics of England for retrospective analysis
and future follow-up regarding their cancer and mortality
status.

**Novel Molecular and Genetic Phenotypes**

Alongside with the conventional epidemiological pheno-
types assessed by questionnaires and clinical visits, the
TwinsUK registry benefits from generous and continued
donation of biological samples by its volunteering partici-
pants. The methods for collection of these biological sam-
ple s have been described previously, and the updated figures
are presented in Table 1. Recently, a wide array of the latest
‘omics’ advances has been applied to subsections of these
samples that makes TwinsUK one of the most uniquely phe-
notyped and deeply genotyped populations in the world. Here we describe some of these advances.

**Genome-Wide Association Studies**

TwinsUK has contributed to many international consor-
tia for genome-wide association analysis of various pheno-
types. Genome-wide scan data using two chips (Ilumina
HumanHap300 BeadChip and Illumina HumanHap610
QuadChip) are available for 5,710 twins. The data have
been fully imputed using ‘HapMap II’ and ‘1000 Genomes’
reference panels (containing ~2.5 and ~16 million sin-
gle nucleotide polymorphisms, respectively). TwinsUK is a
member of many ongoing international consortia for meta-
analysis of various traits, such as GIANT, CHARGE, EN-
GAGE, GEFOS, SUNLIGHT, MolPAGE, VisiGEN, TreatOA,
and SpiroMeta (Aulchenko et al., 2009; Dehghan et al., 2011;
Duffy et al., 2010; Dupuis et al., 2010; Elks et al., 2010;
Evangelou et al., 2011; Ganesh et al., 2009; Hysi et al., 2010;
Kolz et al., 2009; Lango et al., 2010; Lindgren et al., 2009;
Newton-Cheh et al., 2009; Nolte et al., 2009; Padmanabhan
et al., 2010; Panoutsopoulou et al., 2011; Repapi et al., 2010;
Richards et al., 2009a, 2009b; Smith et al., 2010; Speliotes
et al., 2010; Willer et al., 2009; Zhai et al., 2009, 2011).

**Next-Generation Sequencing**

The UK10K study is an ongoing collaboration between
TwinsUK study, the Wellcome Trust Sanger Institute, and
several other collaborators for using the state-of-the-art,
ext-generation sequencing methods to uncover rare gen-
etic variants associated with health and disease. The study
involves whole-genome sequencing of 4,000 healthy people
with well-documented physical characteristics (2,000 twins
from TwinsUK and 2,000 children from ALSPAC study) and
whole-exome (protein-coding regions of DNA) sequencing
of 6,000 people with extreme health problems (obesity, neu-
rological problems, and rare diseases). At present, all twin
samples have been sequenced (6 × depth) and both pheno-
type and sequence data will be publicly available soon. More
details about the study can be accessed at: www.uk10k.org.
Moreover, about 1,000 exome sequences at 30–60 × depth
have been performed for twin participants as part of projects
with Pfizer and the GoT2D consortium. Over 2,000 Exome
chips are currently being performed, mainly for control
purposes in other consortia.

**Epigenetic Markers**

The first epigenetic assessment in TwinsUK was performed
on DNA methylation patterns using Illumina Human-
Methylation27 BeadChip in a sample of 172 female twins.
This array examines 27,578 promoter CpG-sites that map
uniquely across the genome, and some of these sites were
found to be associated with age and age-related pheno-
types (Bell et al., 2012). Currently, the Infinium Hu-
manMethylation450 BeadChip (Illumina) is being applied

---

**TABLE 2**

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>N of measurements</th>
<th>N of participants</th>
<th>N of participants with ≥2 measurements</th>
<th>Maximum number of visits</th>
<th>Duration of follow-up (year)</th>
<th>Maximum duration of follow-up (year)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood pressure</td>
<td>13,180</td>
<td>7,189</td>
<td>3,836</td>
<td>5</td>
<td>7.3 ± 3.3</td>
<td>13.7</td>
</tr>
<tr>
<td>Lipid profile</td>
<td>12,652</td>
<td>6,881</td>
<td>3,585</td>
<td>7</td>
<td>8.5 ± 3.9</td>
<td>16.4</td>
</tr>
<tr>
<td>Electrocardiography</td>
<td>8,083</td>
<td>5,533</td>
<td>1,864</td>
<td>5</td>
<td>8.0 ± 3.1</td>
<td>12.6</td>
</tr>
<tr>
<td>Fasting glucose</td>
<td>16,305</td>
<td>7,731</td>
<td>4,344</td>
<td>11</td>
<td>8.4 ± 3.6</td>
<td>16.8</td>
</tr>
<tr>
<td>Blood insulin</td>
<td>13,650</td>
<td>6,953</td>
<td>3,810</td>
<td>11</td>
<td>8.4 ± 3.6</td>
<td>16.8</td>
</tr>
<tr>
<td>Respiratory function</td>
<td>12,245</td>
<td>7,128</td>
<td>3,326</td>
<td>5</td>
<td>8.7 ± 3.5</td>
<td>16.2</td>
</tr>
<tr>
<td>Hip BMD</td>
<td>15,367</td>
<td>7,025</td>
<td>4,098</td>
<td>12</td>
<td>8.5 ± 3.8</td>
<td>17.5</td>
</tr>
<tr>
<td>Spine BMD</td>
<td>15,489</td>
<td>7,046</td>
<td>4,115</td>
<td>13</td>
<td>8.5 ± 3.8</td>
<td>17.5</td>
</tr>
<tr>
<td>Whole body DXA</td>
<td>13,850</td>
<td>7,292</td>
<td>3,882</td>
<td>7</td>
<td>8.5 ± 3.7</td>
<td>17.5</td>
</tr>
<tr>
<td>Heel QUS</td>
<td>8,299</td>
<td>5,419</td>
<td>1,753</td>
<td>7</td>
<td>3.4 ± 1.1</td>
<td>7.7</td>
</tr>
<tr>
<td>Grip strength</td>
<td>6,861</td>
<td>4,840</td>
<td>1,999</td>
<td>3</td>
<td>3.1 ± 0.7</td>
<td>5.5</td>
</tr>
<tr>
<td>Sexual hormones</td>
<td>5,779</td>
<td>5,350</td>
<td>428</td>
<td>3</td>
<td>5.3 ± 3.0</td>
<td>10.3</td>
</tr>
</tbody>
</table>

Note: BMD = bone mineral density, DXA = dual-energy X-ray absorptiometry, QUS = quantitative ultrasound.
to 500 additional MZ and DZ twin pairs to generate higher-resolution genome-wide DNA methylation profiles. This array includes 485,764 cytosine positions (CpG dinucleotides and CNG sites) across the human genome. Meanwhile, the major ongoing epigenetic project using the TwinsUK population is the EpiTwin study (http://www.epitwin.eu), which uses MeDIP (Methylated DNA immunoprecipitation) sequencing in whole blood samples (Bell & Spector, 2011). This is the largest epigenetic project of its kind, in collaboration with the Beijing Genomics Institute, aiming to assay epigenomic differences in 5,000 adult UK twins aged 16–85 years, discordant and concordant for a wide variety of diseases and environments. Next-generation sequencing has the potential to prove powerful in detecting disease-related methylation differences at a high level of resolution in a sample of this size. The initial targets of the study include obesity, diabetes, allergy, heart disease, osteoporosis, depression, and longevity, but the method can be applied to every common trait or disease.

**Gene Expression Measures**

Eight hundred fifty-six twins with detailed clinical profiles have been biopsied during the HATS clinical visit. This has been done in the context of the MuTHER (Multiple Tissue Human Expression Resource) project, which is a Wellcome Trust funded study designed to understand the mechanisms involved in common trait susceptibility via gene expression across multiple tissues (Nica et al., 2011). Gene expression in three tissues of skin, fat, and lymphoblastoid cell lines have been measured using Illumina’s whole genome expression array (HumanHT-12 version 3) containing 48,803 probes in three technical replicates. Results for expression quantitative trait loci analysis in 856 twins are freely available in the Web site (http://www.muther.ac.uk), and the main paper has recently been published (Grundberg et al., 2012). All of these tissues are now being biopsyed and will be used for Illumina’s genome-wide array platforms. This array includes 485,764 cytosine positions and has been assessed for telomere length using an established and validated quantitative polymerase chain reaction technique. Quality control has now been finalized and the data is available for collaborations.

**Telomere Length**

Telomere length, as a marker of cellular senescence and subsequent cell death, was first measured in 3,256 twins with available genome-wide scans. These measures were derived from the mean of the terminal restriction fragment length by using the Southern blot method on DNA extracted from peripheral leukocytes. This data has contributed to detection of several genes implicated to affect biological age (Codd et al., 2010; Mangino et al., 2009). Recently, a larger sample (4,899 twins aged 16–99 years) has been assessed for telomere length using an established and validated quantitative polymerase chain reaction technique. Quality control has now been finalized and the data is available for collaborations.

**Metabolomic Profiles**

In 2009, fasting serum concentrations of 163 metabolites were measured for 1,270 twins using electrospray ionization tandem mass spectrometry (Biocrates AbsoluteIDQ technology). This targeted panel of metabolites covers a wide range of known lipids, amino acids, sugars, acylcarnitines, and phospholipids. This data has been used in several outstanding studies (Zhai et al., 2010). More recently, a larger sample of 6,055 twins has been assessed using a new method of non-targeted metabolomic analysis. This new platform (Metabolon Inc., Durham, USA) incorporates two separate ultra-high performance liquid chromatography/tandem mass spectrometry injections (optimized for basic and acidic species) and one gas chromatography/mass spectrometry injection per sample. This platform has detected and quantified concentration of 510 small molecules (299 known and 211 unknown molecules) including amino-acids, lipids, carbohydrates, vitamins, nucleotides, peptides, xenobiotics, and steroids. Genome-wide association studies of ~37,000 traits from 60 biochemical pathways in a subsample of this population has identified several genes involved in metabolic individuality in humans and promises significant advances in future functional studies (Suhre et al., 2011).

**Microbiomics**

We have recently started a collaborative National Institutes of Health-funded study with Cornell University, aiming to collect gut flora DNA for analysis with 16S sequencing technology in 5,000 twins. In addition, pilot data assaying microbiome diversity from other human body sites, such as skin, oral, and nasal cavities, as well as gut flora metagenomics are currently underway.

**Future Directions and Collaborations**

Frequent data collection with detailed clinical, biochemical, behavioral, and socio-economic characterization of participants for about two decades provides the opportunity to look at the prospective single-measure and repeated-measure associations for complex diseases and domains of healthy ageing in TwinsUK population. This also offers a unique opportunity to explore personalized medicine. Data collection, database management, biological sample storage, and statistical quality control have been carried out to a high standard. Blood, urine, and DNA sample aliquots from all visits are available for future measurements. We currently use online questionnaires and are actively engaging with our twin participants via e-mail and social networking...
Web sites. Our ‘Volunteer Advisory Panel’ helps informed decisions about the ethics, practicalities, and appropriateness of potential studies.

The TwinsUK registry has a history of numerous successful scientific collaborations, and we remain committed to providing the scientific community with access to the phenotype data from the ‘TwinsUK Resource’. A recent Biomedical Resource Grant from the Wellcome Trust is continuing to fund the core functions of TwinsUK. This will enable access to our publicly funded data from the wider scientific community (the ‘resource’), which will be separate from the individual research projects performed by academics within the Department of Twin Research at KCL. The TwinsUK Resource is opening up access of data, currently harmonizing and standardizing phenotypic data collected over the last 20 years; a subset of the data is already available for full open access via our Web site (http://www.twinsuk.ac.uk/data-access) and a search engine for the available phenotypes has been provided. We have an access committee, which meets weekly and reviews about 20 requests a month (www.twinsuk.ac.uk/data-access/submission-procedure). Researchers are encouraged to find out if TwinsUK resource can help them answer their research questions and get in contact for future collaborations.

Acknowledgments

The authors acknowledge financial support from the Wellcome Trust, the Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London/Arthritis Research Campaign/EC FP6 Programme Grant-512066 (LSHG-CT-2004); MOLPAGE/EC Framework 7 Programme Grant 2008; Treat OA/EC Framework 7 Health-2007-A; EANG/EC Framework 7 Health-2007-2.4.5-4; GEFOS/EC FP6 MRTN-CT-2006-034021; MyEuropa Research Training Network/Chronic Disease Research Foundation (CDRF)/Pfizer Pharmaceuticals/National Health and Medical Research Council (NHMRC)/National Institute of Aging (NIA)/Guide Dogs for the blind Association(GDBA)/Biotechnology and Biological Sciences Research Council (BBSRC). The authors acknowledge the funding and support of the National Eye Institute via an NIH/CIDR genotyping project (R01EY018246-01-PI Terri Young). The authors would also like to thank all the twins who participated and supported this cohort and staff in the Department of Twin Research and Genetic Epidemiology, St. Thomas’ Hospital, King’s College London.

References


